Drug Landscape ›
Immunoglobulin G ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 25,404
Most-reported reactions
Off Label Use — 4,296 reports (16.91%) Fatigue — 2,800 reports (11.02%) Covid-19 — 2,728 reports (10.74%) Headache — 2,518 reports (9.91%) Drug Ineffective — 2,387 reports (9.4%) Pneumonia — 2,300 reports (9.05%) Sinusitis — 2,286 reports (9%) Product Dose Omission Issue — 2,147 reports (8.45%) Inappropriate Schedule Of Product Administration — 2,137 reports (8.41%) Malaise — 1,805 reports (7.11%)
Source database →
Immunoglobulin G in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Immunoglobulin G approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Immunoglobulin G in United States?
Green Cross Corporation is the originator. The local marketing authorisation holder may differ — check the official source linked above.